1174546-71-4

Basic information

• Product Name: tert-butyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl) acetate
• Synonyms: tert-butyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl) acetate
• CAS NO: 1174546-71-4
• Molecular Weight: 803.941
• Mol File: 1174546-71-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl) acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl) acetate(1174546-71-4)
• EPA Substance Registry System: tert-butyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl) acetate(1174546-71-4)

Safety Data

• Hazardous Substances Data: 1174546-71-4(Hazardous Substances Data)

Upstream product

• 67-30-1 tetrac 
• 538-75-0 dicyclohexyl-carbodiimide 
• 75-65-0 tert-butyl alcohol 

Relevant articles and documents

Semisynthesis and pharmacological activities of Tetrac analogs: Angiogenesis modulators

Novel Tetrac analogs were synthesized and then tested. Anti-angiogenesis efficacy was carried out using the Chick Chorioallantoic Membrane (CAM) model and the mouse matrigel model for angiogenesis. Pharmacological activities showed Tetrac can accommodate numerous modifications and maintain anti-angiogenesis activity.

Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells

Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone antagonists and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone antagonists and/or nanoparticulate or polymeric forms thereof.